Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
| ▸ | DRD1 | P21728 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD5 | P21918 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3454630 | 0.93 | USP2 (0.67) | POLBKDM4EABCB1ALDH1A1USP2 | |
| SCHEMBL8555636 | 0.88 | MEN1 (0.62) | POLBKDM4EABCB1DRD1DRD2 | |
| SCHEMBL16676773 | 0.88 | ABCB1 (0.66) | POLBKDM4EABCB1DRD1DRD2 | |
| SCHEMBL1874443 | 0.86 | KDM4E (0.64) | POLBKDM4EABCB1DRD1DRD2 | |
| SCHEMBL8401002 | 0.86 | DRD2 (0.75) | KDM4EABCB1DRD1DRD2DRD3 | |
| SCHEMBL11365759 | 0.86 | DRD2 (0.75) | KDM4EABCB1DRD1DRD2DRD3 | |
| SCHEMBL6044278 | 0.85 | MEN1 (0.72) | POLBKDM4EABCB1DRD1DRD2 | |
| SCHEMBL21681985 | 0.85 | NPC1 (0.63) | POLBKDM4EDRD1DRD4DRD5 | |
| Hydrochloric Acid SCHEMBL8665681 | 0.84 | DRD2 (0.73) | KDM4EABCB1DRD1DRD2DRD3 | |
| SCHEMBL21681926 | 0.84 | POLB (0.62) | POLBKDM4EDRD1DRD4DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
| US-4298603-A | LOCAL ANESTHETICS | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1981-11-03 | — | — | US | disclosed |
| EP-0031632-A1 | O-Aminoalkylsalicylates, process for their preparation, and their pharmaceutical compositions | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | POLB 3076/4885KDM4E 1951/4885ABCB1 2425/4885 |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | POLB 2907/4885KDM4E 3638/4885ABCB1 3205/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | POLB 2907/4885KDM4E 3638/4885ABCB1 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.